Dual Immune Armies in Glaucoma: Microglia and Monocyte-Derived Macrophages

When pathology arises, breakdown of the blood-retinal barrier permits entry of monocyte-derived macrophages (MDMs) into retinal tissue.

• Glaucoma drives progressive retinal ganglion cell loss with pervasive neuroinflammation and disruption of the intraocular immune milieu.
• The retina’s immune environment is distinct, with microglia as resident sentinels under normal conditions.

• Microglia: act as first responders, rapidly activating in early injury, continuously monitoring microenvironmental changes, and initiating the initial inflammatory response.
• Monocyte-derived macrophages (MDMs): function as late reinforcement, infiltrating extensively after barrier disruption to amplify inflammation and contribute to optic nerve damage.
• The two populations form a coordinated, yet heterogeneously functioning, immune network with distinct temporal and mechanistic roles in glaucomatous neurodegeneration.

• Previous work has often treated microglia and MDMs as a single, indistinguishable population, hindering precise targeting for immunomodulation in glaucoma.
• The current synthesis emphasizes systematic comparison of origins, roles, and specific marker profiles of microglia versus MDMs, aiming to delineate their synergistic actions and division of labor across disease stages.

• Highlighting heterogeneity within these two immune cell groups underlines how dynamic interactions contribute to retinal immune imbalance during glaucoma.
• Elucidating the distinct functions at various disease stages seeks to clarify how the retinal immune environment becomes dysregulated and drives optic neuropathy.

• Insights into the precise contributions and timing of microglia and MDMs may inform targeted immunomodulatory strategies intended to protect retinal ganglion cells.
• The work points toward a theoretical basis and future directions for interventions that leverage the coordinated but differentiated roles of resident and infiltrating immune cells to potentially reverse optic nerve damage.

• The article notes ongoing uncertainty about the exact molecular markers and functional states distinguishing microglia from MDMs across glaucoma stages.
• Further research is needed to translate these mechanistic insights into targeted therapies that can selectively modulate the dual immune armies without compromising essential retinal immunity.